文献速递骨软组织肉瘤与黑色素瘤

衰老成纤维细胞脂质代谢改变通过FATP2诱导黑色素瘤靶向治疗耐药

Changes in Aged Fibroblast Lipid Metabolism Induce Age-Dependent Melanoma Cell Resistance to Targeted Therapy via the Fatty Acid Transporter FATP2.
PubMed 文献 · Cancer Discov · 2020-06-04

老年(>50岁)黑色素瘤患者预后及靶向治疗应答较差,部分由衰老微环境驱动。衰老真皮成纤维细胞增加分泌中性脂质(尤其是神经酰胺),黑色素瘤细胞通过脂肪酸转运体FATP2摄取脂质,改变线粒体代谢并介导对BRAF/MEK抑制的耐药;抑制FATP2可克服动物模型中的年龄相关耐药并延长生存。

要点

  • 衰老成纤维细胞分泌中性脂质(尤其神经酰胺)增加。
  • 黑色素瘤细胞经FATP2摄取脂质并改变线粒体代谢。
  • 抑制FATP2可克服BRAF/MEK抑制的年龄相关耐药。

核心结论

  • 衰老微环境通过成纤维细胞脂质分泌与黑色素瘤细胞FATP2摄取介导年龄相关靶向治疗耐药。
  • 抑制FATP2可克服动物模型中对BRAF/MEK抑制的年龄相关耐药并延长老年动物生存。

研究设计与样本

  • 研究在动物模型中验证衰老微环境对黑色素瘤靶向治疗耐药的影响及FATP2的作用。

主要发现

  • 衰老真皮成纤维细胞增加分泌中性脂质,尤其是神经酰胺。
  • 黑色素瘤细胞暴露于衰老成纤维细胞脂质分泌组或与衰老成纤维细胞共培养时,通过FATP2增加脂质摄取。
  • FATP2在衰老微环境的黑色素瘤细胞中上调,参与脂质合成与积累。
  • 在衰老微环境中阻断黑色素瘤细胞FATP2可抑制脂质积累并干扰线粒体代谢。
  • 抑制FATP2可克服动物模型中对BRAF/MEK抑制的年龄相关耐药、消除肿瘤复发并显著延长老年动物生存时间。

临床怎么用

  • 在老年黑色素瘤患者中需考虑衰老微环境驱动的靶向治疗耐药。
  • FATP2可作为克服年龄相关BRAF/MEK抑制耐药的潜在靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Older patients with melanoma (>50 years old) have poorer prognoses and response rates to targeted therapy compared with young patients (<50 years old), which can be driven, in part, by the aged microenvironment. Here, we show that aged dermal fibroblasts increase the secretion of neutral lipids, especially ceramides. When melanoma cells are exposed to the aged fibroblast lipid secretome, or cocultured with aged fibroblasts, they increase the uptake of lipids via the fatty acid transporter FATP2, which is upregulated in melanoma cells in the aged microenvironment and known to play roles in lipid synthesis and accumulation. We show that blocking FATP2 in melanoma cells in an aged microenvironment inhibits their accumulation of lipids and disrupts their mitochondrial metabolism. Inhibiting FATP2 overcomes age-related resistance to BRAF/MEK inhibition in animal models, ablates tumor relapse, and significantly extends survival time in older animals. SIGNIFICANCE: These data show that melanoma cells take up lipids from aged fibroblasts, via FATP2, and use them to resist targeted therapy. The response to targeted therapy is altered in aged individuals because of the influences of the aged microenvironment, and these data suggest FATP2 as a target to overcome resistance.See related commentary by Montal and White, p. 1255.This article is highlighted in the In This Issue feature, p. 1241.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Alicea GM, Rebecca VW, Goldman AR, et al. Changes in Aged Fibroblast Lipid Metabolism Induce Age-Dependent Melanoma Cell Resistance to Targeted Therapy via the Fatty Acid Transporter FATP2. Cancer Discov. 2020. PMID: 32499221. doi:10.1158/2159-8290.CD-20-0329

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。